Kerala Researchers Develop New Drug for Leukaemia
Amrita University, Kochi have developed dual-targeted nano-medicine
Researchers at the Centre for Nanoscience and Molecular Medicine of Amrita University, Kochi have developed dual-targeted nano-medicine useful to treat drug resistant chronic myeloid leukaemia known as CML. The currently using drug for CML, imatinib, is useful for only two years after which the disease resists the drug as the BCR-ABL oncogene (a gene with the potential to cause cancer) changes its characteristics due to the inherited mutation.
Molecular Pharmaceutics, a publication of American Chemical Society, has published the results of the nanomedicine following which US based M D Anderson Cancer Centre has come forward to conduct trials on animals.